Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 6;5(1):16.
doi: 10.3390/mps5010016.

Development of Primary Monolayer Cell Model and Organotypic Model of Uterine Leiomyoma

Affiliations

Development of Primary Monolayer Cell Model and Organotypic Model of Uterine Leiomyoma

Natalia Shved et al. Methods Protoc. .

Abstract

Cellular technologies are one of the most promising areas of biomedicine, which is based on the isolation of cells of various types, followed by their cultivation and use, or the use of their metabolic products, for medical purposes. Today, a significant part of biomedical research is carried out in vitro. On the other hand, organotypic culture can be used as a powerful model system and can complement cell culture and in vivo studies in different biomedical applications. Uterine leiomyoma (UL) is a very common benign tumor and often leads to many reproductive complications. Herein we describe a fast and reliable method of isolation and UL primary cells culturing along with the development of a UL organotypic model. We propose the usage of UL primary cells in experimental work at a first passage to prevent loss of driver mutations in MED12 and HMGA2 genes. New optimized conditions for the growth and maintenance of 2D and 3D models of uterine leiomyoma in vitro are suggested.

Keywords: HMGA2; MED12; cell model; organotypic model; uterine leiomyoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Representative scheme of UL cellular and organotypic model development.
Figure 2
Figure 2
Representative microphotographs of the cellular and organotypic UL models: (a) primary UL cells at p0 (magnification × 100; scale bar is 100 µm); (b) typical appearance of leiomyoma fragments.
Figure 3
Figure 3
Detection of heterozygous mutation c.131G >A in MED12 gene in the same primary UL cell line at different passages: (a) p1; (b) p2; (c) p3; (d) control–healthy myometrium.
Figure 4
Figure 4
Measurement of HMGA2 gene expression (fold change relative to reference β-actin gene) in two independent primary UL cell lines at different passages.
Figure 5
Figure 5
Histological characterization of the organotypic model. Hematoxyline-eosine stained cryosections of UL fragments after 7 (a), 14 (b), and 21 (c) days of culture (magnification × 100; scale bar is 200 µm). Arrows mark extracellular matrix.

Similar articles

Cited by

References

    1. Ohara N. Action of progesterone receptor modulators on uterine leiomyomas. Clin. Exp. Obstet. Gynecol. 2008;35:165–166. - PubMed
    1. Zhu Y., Zhang T., Xie S., Tu R., Cao Y., Guo X., Zhou J., Zhou X., Cao L. Gestrinone inhibits growth of human uterine leiomyoma may relate to activity regulation of ERα, Src and P38 MAPK. Biomed. Pharmacother. 2012;66:569–577. doi: 10.1016/j.biopha.2012.02.003. - DOI - PubMed
    1. Segars J.H., Parrott E.C., Nagel J.D., Guo X.C., Gao X., Birnbaum L.S., Pinn V.W., Dixon D. Proceedings from the third national institutes of health international congress on advances in uterine leiomyoma research: Comprehensive review, conference summary and future recommendations. Hum. Reprod. Update. 2014;20:309–333. doi: 10.1093/humupd/dmt058. - DOI - PMC - PubMed
    1. Shtykalova S.V., Egorova A.A., Maretina M.A., Freund S.A., Baranov V.S., Kiselev A.V. Molecular Genetic Basis and Prospects of Gene Therapy of Uterine Leiomyoma. Russ. J. Genet. 2021;57:1002–1016. doi: 10.1134/S1022795421090118. - DOI
    1. Nadine Markowski D., Tadayyon M., Bartnitzke S., Belge G., Maria Helmke B., Bullerdiek J. Cell cultures in uterine leiomyomas: Rapid disappearance of cells carrying MED12 mutations. Genes Chromosomes Cancer. 2014;53:317–323. doi: 10.1002/gcc.22142. - DOI - PubMed

LinkOut - more resources